Literature DB >> 32632097

The efficacy and safety of CAR-T cell therapy in patients with refractory ALL and concomitant HBV infection.

Peilong Lai1,2,3, Xiaomei Chen1, Le Qin2, Zhiwu Jiang2, Chenwei Luo1, Xin Huang1, Sujing Wu1, Wei Ling1, Yulian Wang1, Jinghua Wang1, Chenxin Deng1, Lisi Huang1, Lingji Zeng1, Zesheng Lu1, Liye Zhong1, Pengjun Liao1, Minming Li1, Dongmei Chen2, Suxia Geng1, Ping Wu1, Zhaoyang Tang4, Duanqing Pei2,3, Xin Du5, Peng Li6,7, Jianyu Weng8.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32632097     DOI： 10.1038/s41375-020-0952-4

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  3 in total

1.  [The consensus on the prophylaxis and treatment of HBV reactivation in B or plasma cell-directed CAR-T cell therapy(2021)].

Authors: 
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2021-06-14

2.  Cytomegalovirus Retinitis and Retinal Detachment following Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory Multiple Myeloma.

Authors:  Cheng Zu; Yufeng Xu; Yiyun Wang; Mingming Zhang; Houli Zhao; Xiaoyun Fang; He Huang; Yongxian Hu
Journal:  Curr Oncol       Date:  2022-01-24       Impact factor: 3.677

3.  Donor-Derived CD7 CAR-T Therapy Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Acute T-Lymphocytic Leukemia Associated With Hepatitis B: A Case Report.

Authors:  Zhihui Li; Fanqiao Meng; Jing Li; Tong Wu
Journal:  Front Immunol       Date:  2022-07-12       Impact factor: 8.786
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.